Abstract: BACKGROUND: Tumor suppressor gene (TSG) alterations prognosticate inferior survival in metastatic hormone-sensitive prostate cancer (mHSPC) and may affect response to …
Abstract: BACKGROUND: Germline pathogenic variants can inform targeted therapy for metastatic prostate cancer (mPC), and improve cancer early detection and risk reduction for …
Abstract: Precision healthcare aims to tailor disease prevention and early detection to individual risk. Prostate cancer screening may benefit from genomics-informed approaches. We …
Abstract: BACKGROUND: Agent Orange exposure (AOE) is considered a presumptive cause of prostate cancer (PCa) in the Veterans Affairs (VA) population; however, cohort studies …
Abstract: IMPORTANCE: National guidelines recommend next-generation sequencing (NGS) of tumors in patients diagnosed with metastatic prostate cancer (mPCa) to identify potential …
Abstract: Background: We aimed to assess real-world efficacy of the PARP inhibitor, olaparib, in US Veterans with metastatic prostate cancer (mPC) by leveraging the national data …